- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02288936
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer (PREMIERE)
Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy
Prostate cancer is the most common non-skin tumor diagnosed in men and the second leading cause of cancer death in men in Western countries.
Between 10-20% of patients are diagnosed at metastatic stage and about half of those diagnosed in early stages will develop metastases.
After the clinical benefit of mitoxantrone and the improved survival of 2-3 months provided by docetaxel in first line, the second search is driven to look for effective second lines treatments. In recent years, there are new drugs for the treatment of prostate cancer, revolutionizing the therapeutic sequence and survival.
Thus, androgen deprivation therapy, treatment of choice, induces an improvement of symptoms in approximately 70-80% of patients, but it is limited by the development of mechanisms of resistance to androgen deficiency. Docetaxel was the first chemotherapy drug to increase survival in patients with metastatic prostate cancer. The second cytotoxic drug approved in the second line treatment of metastatic CRPC has been cabazitaxel.
Enzalutamide improves survival in patients with metastatic CRPC who had progressed to chemotherapy and also in patients who had not received chemotherapy.
To date, there are no biomarkers available that allow us to identify which patients from a clinical or molecular view are those that will be able to benefit from the treatment options currently available. The presence of the TMPRSS2-ETS rearrangement has been shown to correlate with efficacy in clinical practice abiraterone.
There is scientific and preclinical background that makes one suspect that the molecular alteration may influence the same way enzalutamide antiandrogen activity, but it has not been determined to date.
The objective of this study is to determine whether the efficacy and safety of enzalutamide, when administered to patients with castration resistant prostate cancer prior to administration of docetaxel is influenced by the presence or absence of the fusion gene TMPRSS2- ETS.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic i Provincial de Barcelona
-
Barcelona, Spain
- Hospital Parc Tauli
-
Córdoba, Spain, 14004
- Complejo Hospitalario Regional Reina Sofía
-
León, Spain, 24080
- Complejo Asistencial Universitario de León
-
Lugo, Spain, 27003
- Hospital Universitario Lucus Augusti
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28034
- Hospital Ramón y Cajal
-
Murcia, Spain, 30008
- Hospital General Universitario J.M. Morales Meseguer
-
Málaga, Spain, 29010
- Complejo Hospitalario de Especialidades Virgen de la Victoria
-
Ourense, Spain, 32005
- Complexo Hospitalario Universitario de Ourense
-
Sevilla, Spain, 41013
- Complejo Hospitalario regional Virgen del Rocio
-
Valencia, Spain, 46009
- Fundacion Instituto Valenciano de Oncologia
-
Zaragoza, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Hospital Universitari Germans Trias I Pujol de Badalona
-
-
Islas Baleares
-
Palma de Mallorca, Islas Baleares, Spain, 07120
- Hospital Universitari Son Espases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18 years and above, willing and able to provide written informed consent.
- Prostate adenocarcinoma with histological or cytological confirmation without neuroendocrine differentiation nor small cell characteristics
- Androgen deprivation therapy with GnRH analogs or bilateral orchiectomy (pharmacological or surgical castration). Patients without bilateral orchiectomy must follow a GnRH analog therapy during the trial.
- Testosterone serum level <= 1,73 nmol/L (50 ng/dL) in screening visit.
- Patients under bisphosphonate therapy must have received stable doses for the last 4 weeks.
- Progression disease at inclusion, defined by one or more of the following three criteria during androgen deprivation therapy (according with the criterion nº 3): - PSA progression defined as two elevation of the PSA serum level with >=1 week between each measure. Patients who have received an antiandrogen must present disease progression (>=4 weeks since the last dose of flutamide or >=6 weeks since the last dose of bicalutamide or nilutamide). PSA value in screening visit must be >=2 μg/L (2 ng/mL). - Soft tissue progression defined by RECIST 1.1 criteria - Bone lesion progression defined by PCWG2 criteria, with two or more new lesions in a scintigraphy
- Metastatic disease with bone lesions detected by scintigraphy, or measurable soft tissue lesions by CT/MR. Patients with ganglionar disease will be suitable if they have at least one ganglionar lesion with smallest diameter > 2,5 cm.
- Patients without previous cytotoxic chemotherapy for prostate cancer
- Patients without previous abiraterone acetate therapy for prostate cancer - - Asymptomatic patient or mild symptomatic about prostate cancer, (answer in the question nº 3 of the Brief Pain Inventory Short From < 4) 11. ECOG = 0-1.
- Life expectancy of at least 6 months
- Patient must be able to swallow the investigation product and to follow the protocol requirements.
- Biomarker study informed consent
Exclusion Criteria:
- Active infection or other medical condition which, in the opinion of the investigator, would preclude participation in this trial.
- Known brain metastasis or leptomeningeal active involvement
- Other malignancy in the last five years, except non-melanoma skin cancer treated and resolved.
- Hematologic parameters: - Absolute neutrophil count <=1500/μL - Platelet count <100 000/μL - Haemoglobin < 5,6 mmol/L (9 g/dL)
- Liver function: Serum bilirubin, SGPT/ALT or SGOT/AST > 2,5 x ULN
- Renal function: Creatinine >177 μmol/L (2 mg/dL).
- Serum albumin <30 g/L (3,0 g/dL)
- History of epilepsy or other medical condition which could cause an epileptic crisis as syncope or transient ischemic attack in the last twelve months.
- Clinically significant cardiovascular disease.
- Known gastrointestinal (GI) disease that could interfere with the GI absorption.
- Significant surgery within 4 weeks before enrollment.
- Use of opioids to control cancer pain within 4 weeks before enrollment.
- Radiation therapy for treatment of the primary tumor in the last 3 weeks before enrollment
- Radiation therapy for treatment of metastases in the last two months
- Radionuclide therapy for treatment of bone metastasis
- Prior flutamide treatment within 4 weeks before enrollment
- Bicalutamide or nilutamide therapy within 6 weeks before enrollment
- 5-a reductase inhibitors, estrogen o cyproterone therapy within 4 weeks before enrollment
- Biologic therapy or other antitumoral drugs for the treatment of CRPC in the last 4 weeks
- History of cancer progression with ketoconazole
- Prior therapy or enrollment in a trial with an investigational product which blocks androgen synthesis (abiraterone, TAK-700, TAK-683, TAK-448) or blocks androgen receptors (ARN507, BMS 641988).
- Included in a previous trial with enzalutamide (MDV3100).
- Administration of an investigational drug in the last 4 weeks before enrollment
- Use of phytotherapy products which hormonal activity against prostate cancer or which reduce PSA levels, or systemic corticosteroids in a dose greater than the equivalent of prednisone 10mg/day, within 4 weeks before enrollment
- Hereditary fructose intolerance
- Any condition which, in the opinion of the investigator, would preclude participation in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Enzalutamide
Enzalutamide 160 mg/day
|
Enzalutamide 160 mg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSA progression free survival
Time Frame: Up to 18 months
|
Evaluate PSA progression (PCWG2 criteria) from date of patient inclusion until the date of first documented PSA progression or date of death from any cause, whichever came first, assessed up to 18 months.
|
Up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of individual events (hematologic events and not hematologic events) per patient
Time Frame: Up to 12 months
|
Number of events per patient
|
Up to 12 months
|
Time to PSA response
Time Frame: Up to 18 months
|
Time from start of treatment to PSA progression (PCWG2 criteria)
|
Up to 18 months
|
PSA response rate
Time Frame: Up to 18 months
|
PSA response according to PCWG2 criteria, as % of patients with PSA response
|
Up to 18 months
|
Radiologic progression free survival
Time Frame: Up to 18 months
|
Radiologic progression free survival according RECIST 1.1 criteria, from date of patient inclusion until the date of first documented radiologic progression or date of death from any cause, whichever came first, assessed up to 18 months.
|
Up to 18 months
|
Soft tissue response
Time Frame: Up to 18 months
|
Soft tissue response according RECIST 1.1 criteria
|
Up to 18 months
|
Time until the beginning of cytotoxic chemotherapy
Time Frame: Up to 18 months
|
Time from date of patient inclusion until the date of the start of cytotoxic chemotherapy
|
Up to 18 months
|
Collaborators and Investigators
Investigators
- Study Director: Enrique Grande, MD, Hospital Universitario Ramón y Cajal
Publications and helpful links
General Publications
- Jayaram A, Wingate A, Wetterskog D, Conteduca V, Khalaf D, Sharabiani MTA, Calabro F, Barwell L, Feyerabend S, Grande E, Martinez-Carrasco A, Font A, Berruti A, Sternberg CN, Jones R, Lefresne F, Lahaye M, Thomas S, Joshi S, Shen D, Ricci D, Gormley M, Merseburger AS, Tombal B, Annala M, Chi KN, De Giorgi U, Gonzalez-Billalabeitia E, Wyatt AW, Attard G. Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. JCO Precis Oncol. 2019 Sep 24;3:PO.19.00123. doi: 10.1200/PO.19.00123. eCollection 2019.
- Wu A, Cremaschi P, Wetterskog D, Conteduca V, Franceschini GM, Kleftogiannis D, Jayaram A, Sandhu S, Wong SQ, Benelli M, Salvi S, Gurioli G, Feber A, Pereira MB, Wingate AM, Gonzalez-Billalebeitia E, De Giorgi U, Demichelis F, Lise S, Attard G. Genome-wide plasma DNA methylation features of metastatic prostate cancer. J Clin Invest. 2020 Apr 1;130(4):1991-2000. doi: 10.1172/JCI130887.
- Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, Gonzalez Del Alba A, Mellado B, Fernandez-Calvo O, Mendez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Saez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017 Jul 1;28(7):1508-1516. doi: 10.1093/annonc/mdx155.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOG-MIE-2014-04
- 2014-003192-28 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone-refractory Prostate Cancer
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Peking UniversityWithdrawnHormone Refractory Prostate CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownHormone Refractory Prostate CancerChina
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
British Columbia Cancer AgencyCompletedHormone Refractory Prostate CancerCanada
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
Clinical Trials on Enzalutamide
-
ESSA PharmaceuticalsRecruitingProstate CancerCanada, United States, Australia
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedProstate Cancer | Pharmacokinetics of EnzalutamideUnited States
-
Radboud University Medical CenterActive, not recruitingProstatic Neoplasms, Castration-ResistantNetherlands
-
Groupe Hospitalier Pitie-SalpetriereCompletedEpilepsy | Prostate Cancer | Neuropathy | EncephalopathyFrance
-
Andreas JosefssonGöteborg University; Umeå University; Sahlgrenska University Hospital, Sweden; Sundsvall... and other collaboratorsTerminated
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
-
Macquarie University, AustraliaUnknown
-
Translational Research Center for Medical Innovation...Kagawa UniversityCompleted
-
Fundación Canaria de Investigación SanitariaHospital Universitario de CanariasUnknown
-
National Cancer Institute (NCI)Terminated